Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET
Company Participants
George Grofik - SVP, Head, Investor Relations and Communications
Pablo Legorreta - Founder & CEO
Marshall Urist - EVP, Head-Research and Investments
Chris Hite - EVP, Vice Chairman
Terry Coyne - EVP & CFO
Conference Call Participants
Hardik Parikh - JPMorgan
Geoff Meacham - Citi
Michael DiFiore - Evercore
Terence Flynn - Morgan Stanley
Michael Nedelcovych - TD Cowen
Chris Shibutani - Goldman Sachs
Ash Verma - UBS
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter Earnings Conference Call. I would now like to turn the call over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead, sir.
George Grofik
Good morning, and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's Third Quarter 2024 results. You can find the press release with our earnings results and slides to this call on the Investors page of our website at royaltypharma.com.
Moving to Slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. I refer you to our most recent 10-Q on file with the SEC for a description of these risks.
All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements.
Non-GAAP liquidity measures will be used to help you understand our financial results. The reconciliation of these measures to our GAAP financials is provided in the earnings press release available on our website.
And with that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta, Founder and Chief Executive Officer; Marshall Urist, EVP, Head of Research and Investments; Chris Hite, EVP, Vice Chairman; and Terry Coyne, EVP, Chief Financial Officer.
Pablo will discuss key highlights, after which Marshall and Chris will provide portfolio updates, focusing our progress with synthetic royalty transactions. Terry will then review the financials. And following concluding remarks from Pablo, we will hold a Q&A session.
And with that, I'd like to turn the call over to Pablo.
Pablo Legorreta
Thank you, George, and welcome to everyone on the call. I am delighted to report another excellent quarter of execution against our strategy as the leading funder of innovation in life sciences.